Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

BACKGROUND: Talimogene laherparepvec (T-VEC), an oncolytic virus, was designed to selectively replicate in and lyse tumor cells, releasing tumor-derived antigen to stimulate a tumor-specific immune response. METHODS: In this phase II study in patients with unresectable stage IIIB–IV melanoma, we eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Malvehy, Josep, Samoylenko, Igor, Schadendorf, Dirk, Gutzmer, Ralf, Grob, Jean-Jacques, Sacco, Joseph J, Gorski, Kevin S, Anderson, Abraham, Pickett, Cheryl A, Liu, Kate, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011715/
https://www.ncbi.nlm.nih.gov/pubmed/33785610
http://dx.doi.org/10.1136/jitc-2020-001621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011715/
https://www.ncbi.nlm.nih.gov/pubmed/33785610
http://dx.doi.org/10.1136/jitc-2020-001621

Ejemplares similares